Full credit to jad;
This is not an over reaction. This is shorts reacting to getting ruined in a couple of weeks. Per the release: "In the near term we plan to report top-line results from our phase 2 clinical trial of ARIKAYCE to treat NTM lung infections. Following the release of these data, we expect to have discussions with regulatory authorities in the U.S. and Europe regarding a path forward to filing for approval. In the interim, we have initiated a comprehensive education campaign to raise awareness of NTM and to increase accurate and early diagnosis," added Mr. Lewis. "It is our goal to be the leader in this globally uncontested orphan disease market."
Does anyone think they will initiate discussions without positive results? Does anyone think they actually doing an "educational" program (translation - this is a pre-sales program) and does anyone think they would state their goal to own NTM if results weren't supportive. This isn't that tough to read. It's not even between the lines anymore. Less
Yes, the story behind the numbers today is compelling. I expect very good NTM data and a double of the pps by May. WL knows exactly what he is doing and even more important, what he has in hand.................the start of a powerful pipeline.